Skip to main content

Table 1 Inclusion and exclusion criteria

From: Individualised short-term therapy for adolescents impaired by attention-deficit/hyperactivity disorder despite previous routine care treatment (ESCAadol)—Study protocol of a randomised controlled trial within the consortium ESCAlife

Inclusion criteria

• Age 12;0 to 17;11 years

• ADHD according to DSM-5 criteria, assessed with a structured clinical interview

• Patient has been in ADHD routine care for a minimum of 6 months (does not have to be the year immediately preceding the study; routine care defined as treatment aimed at ADHD symptoms as prescribed or provided by a child and adolescent psychiatrist, psychotherapist or paediatrician)

• No sufficient benefit from previous interventions developed for the treatment of ADHD, i.e. still substantial impairment (CGI-S ≥ 4) under current treatment

• Patients and primary caregiver speak sufficient German for psychotherapy

Exclusion criteria

• IQ < 80, assessed with the Wechsler Nonverbal Scale of Ability [101, 102]

• Comorbidity: pervasive developmental disorder, schizophrenia, bipolar disorder, severe depressive episode

• Need for inpatient treatment

• After TAU phase: intensive psychotherapy on a biweekly or more intensive basis

• After TAU phase: psychopharmacological medication which is not constant or not licensed for the treatment of ADHD or comorbid conditions